Amy M. Bain, Pharm.D., BCPS
Reportable Conflicts of Interests: None
Disclosure of Financial Conflicts of Interest: None
Education:
NIH Clinical Scholars and Masters Degree in Clinical Science Program
The University of Texas Southwestern Medical Center
Dallas, Texas; In-progress
Doctor of Pharmacy
Medical University of South Carolina
College of Pharmacy; Charleston, SC
First Honor Graduate
Bachelors of Science in Biology
College of Charleston; Charleston, SC
Magna cum laude
Post Graduate or Residency Training:
ASHP Accredited 2-year Pharmacotherapy Specialty Residency
Texas Tech University Health Sciences Center School of Pharmacy Dallas Fort Worth Regional Campus and Dallas Veterans Affairs Medical Center; Dallas, TX. Program Director: Anthony J. Busti, Pharm.D., BCPS
Fellowship and Board Certifications:
Board Certified Pharmacotherapy Specialist
Board of Pharmaceutical Specialties
Advanced Cardiac Life Support; American Heart Association
Basic Life Support; American Heart Association
Current Position or Practice Site:
Assistant Professor
Texas Tech University Health Sciences Center
School of Pharmacy Dallas/Fort Worth Regional Campus
Dallas, Texas
Clinical Pharmacist – Infectious Diseases & Cardiovascular Pharmacotherapy
Department of Infectious Diseases
Dallas VA Medical Center
Dallas, Texas
Professional Memberships:
National Lipid Association (NLA), 2007 – present
Southwest Lipid Association (SWLA), 2007 – present
American College of Clinical Pharmacy (ACCP) 2006 – present
Dallas Fort Worth Chapter of ACCP 2006 – present
American Society of Health-Systems Pharmacists (ASHP)
Rho Chi Honor Society – Alpha Iota chapter 2004 – present
Christian Pharmacy Fellowship International – founding member 2002 – 2006
Publications:
Nguyen ST, Bain AM, Bedimo RG, Hall RG, Busti AJ (senior author). Rapid elevation of triglycerides after initiation of fosamprenavir/ritonavir in an HIV-negative patient with baseline hypertriglyceridemia. J Clin Lipidology 2008;[in-press].
Busti AJ, Bain AM, Hall RG, Bedimo RG, Meek C, Leff R. The effect of atazanavir/ritonavir and fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin [Original Research]. J Cardivasc Pharmacol 2008;51(6):605-610.
Rahman AP, Eaton SA, Nguyen ST, Bain AM, Payne KD, Bedimo RG, Busti AJ (senior author). The lipid lowering effects of simvastatin in NNRTI-based HAART regimens in HIV-infected patients compared to non-HIV-infected patients [Original Research]. Pharmacotherapy 2008;28(7):913-9.
Bain AM, White E, Rutherford S, Rahman AP, Busti AJ (senior author). Treatment of antiretroviral-associated dyslipidemia: utilizing a multi-modal, evidence-based approach to achieve lipid targets. Case report and mini-review. Pharmacotherapy 2008;28(7):932-8.
Hall RG, Payne KD, Rahman AP, Bain AM, Nguyen ST, Eaton SA, Busti AJ. A multicenter evaluation of vancomycin dosing in tertiary medical centers [Original Research]. Am J Med 2008;121(6):515-8.
Nguyen ST, Eaton SA, Bain A, Payne K, Rahman A, Herrington J, Maclayton D, Rodriguez-Barradas M, Busti AJ (senior author). The lipid lowering efficacy and safety after a switch to an atazanavir/ritonavir based HAART in HIV-infected patients: a multi-center retrospective study [Original Research]. Pharmacotherapy 2008;28(3):323-330.
Bain AM, Payne KD, Rahman AP, Bedimo RG, Maclayton D, Rodriguez-Barradas M, Busti AJ (senior author). The lipid lowering efficacy of switching within non-nucleoside reverse transcriptase inhibitors in HIV-infected patients [Original Research]. Am J Infect Dis 2008;4(2):147-151.
Eaton SA, Rahman AP, Bain AM, Nguyen ST, Payne, KD, Busti AJ (senior author). Efficacy of pravastatin in non-nucleoside reverse transcriptase inhibitor (NNRTI) and protease inhibitor (PI)-based HAART in HIV-infected patients [Original Research]. Am J Infect Dis 2008;4(2):124-130.
Chastain L, Bain A, Edwards K, Bedimo R, Busti AJ (senior author). A retrospective study of the lipid lowering efficacy and safety of ezetimibe added to HMG-CoA reductase therapy in HIV-infected patients with hyperlipidemia [Original Research]. J Clin Lipidology 2007;1:634-639.
Presentations (National, State and Local):
National
Bain AM, Payne KD, Rahman AP, Bedimo R, Maclayton DO, Rodriguez-Barradas M, Busti AJ. A multicenter retrospective study of the lipid-lowering efficacy and safety of switching within the NNRTI class in HIV-infected patients (poster presentation). 2007 National Lipid Association Annual Scientific Sessions May 31 - June 3rd, Scottsdale, AZ. Recipient of 2007 NLA Young Investigator Award – awarded at 2007 Scientific Sessions Meeting in Scottsdale, AZ
Nguyen ST, Eaton SA, Bain AM, Payne K, Rahman A, Bedimo R, Herrington J, Busti AJ. A multi-center retrospective study on the clinical efficacy and safety on lipid Lowering effects after a switch to an atazanavir/ritonavir based HAART regimen (poster presentation). 2007 National Lipid Association Annual Scientific Sessions May 31 - June 3rd, Scottsdale, AZ.
Eaton SA, Rahman AP, Bain AM, Nguyen ST, Payne, KD, Busti AJ. A retrospective evaluation of the lipid effects of pravastatin in NNRTI and PI–based HAART regimens in HIV-positive patients (poster presentation). 2007 National Lipid Association Annual Scientific Sessions May 31 - June 3rd 2007 Scottsdale, AZ.
Rahman AP, Eaton SA, Nguyen ST, Bain AM, Busti AJ. A retrospective study evaluating the safety and efficacy of simvastatin in treating hyperlipidemia in HIV-infected patients on efavirenz based HAART (poster presentation). 2007 National Lipid Association Annual Scientific Sessions May 31 - June 3, 2007, Scottsdale, AZ.
Bain AM, Payne KD, Rahman AP, Bedimo R, Busti AJ. Preliminary results from a retrospective study of the lipid-lowering efficacy and safety of switching within the NNRTI class in HIV-infected patients (poster presentation). ACCP Spring Practice and Research Forum Meeting. April 21-25, 2007, Memphis TN.
Chastain L, Bain AM, Edwards K, Bedimo R, Busti AJ. A retrospective study of the lipid-lowering efficacy and safety of ezetemibe added to HMG-CoA reductase therapy in HIV-infected patients with hyperlipidemia. ACCP Spring Practice and Research Forum Meeting. April 21-25, 2007, Memphis TN.
State Level
Bain AM, Payne KD, Rahman AP, Bedimo R, Maclayton DO, Rodriguez-Barradas M, Busti AJ. A multicenter retrospective study of the lipid-lowering efficacy and safety of switching within the NNRTI class in HIV-infected patients (platform presentation). ALCALDE XXI Southwest Leadership Conference. April 19-20, 2007. San Antonio, TX.
Payne K, Nguyen ST, Eaton SA, Bain AM, Busti AJ, Hall R . A multi-center retrospective evaluation of vancomycin dosing in tertiary medical centers. ALCALDE XXI Southwest Leadership Conference. April 19-20, 2007. San Antonio, TX.
Local Level
Management of dyslipidemia in the HIV patient: the role of antiretroviral switching strategies. Texas Tech University Residency Programs Resident Rounds Seminar Series. September 29, 2006.
Pharmacokinetic drug interactions: beyond the cytochrome P450 system. Texas Tech University Residency Programs Resident Rounds Seminar Series. August 31, 2007.
Antiretroviral – Antidepressant drug interactions: what psychiatrists need to know. Presented to the Dallas VA Medical Center inpatient geriatric psychiatry team. 10/06.
Personality Disorders. Presented on general psychiatry rotation to Clinical Pharmacy Specialist, Pharmacy students and Residents 12/06.
Acute renal failure: etiology, identification and management. Presented on MICU rotation to Clinical Pharmacy Specialist and 4th year pharmacy students. 01/07.
Pharmacotherapy of human immunodeficiency virus. Provided to Texas Tech-DFW Pharmacy Practice and Specialty Residents as part of the Board Certification Review Series. June 8, 2007.
Non-prescription contraception. Invited lecture to 1st year Pharm.D. Candidates for Texas Tech University Pharmaceutical Care I course (PHAR 1301). 02/07.
Erythropoesis stimulating agents. Drug utilization evaluation presented at the VA North Texas Healthcare System Pharmacy and Therapeutics committee meeting. 04/07.
Systematic review and meta-analysis. Inservice provided to Dallas VA Medical Center pharmacy staff and Texas Tech University Pharm.D. faculty. 03/07.
Temsirolimus for treatment of renal cell carcinoma. Inservice provided to inpatient Hematology/Oncology team. 06/07.
Residency training: the future of pharmacy practice. Keynote address at the 2007 Texas Tech University School of Pharmacy Rho Chi Honor Society induction ceremony. 02/07.
(Last updated: 2/9/2009)
